Boston Scientific Business Combination, Contingent Consideration, Liability, Noncurrent increased by 2.4% to $301.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 176.1%, from $109.00M to $301.00M. Over 4 years (FY 2020 to FY 2024), Business Combination, Contingent Consideration, Liability, Noncurrent shows a downward trend with a -10.9% CAGR.
other_business_combination_contingent_consideration_liab_1ff57c| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $54.00M | $195.00M | $197.00M | $63.00M | $86.00M | $95.00M | $75.00M | $10.00M | $10.00M | $10.00M | $100.00M | $90.00M | $118.00M | $109.00M | $108.00M | $100.00M | $294.00M | $301.00M |
| QoQ Change | — | +261.1% | +1.0% | -68.0% | +36.5% | +10.5% | -21.1% | -86.7% | +0.0% | +0.0% | +900.0% | -10.0% | +31.1% | -7.6% | -0.9% | -7.4% | +194.0% | +2.4% |
| YoY Change | — | — | — | — | +59.3% | -51.3% | -61.9% | -84.1% | -88.4% | -89.5% | +33.3% | +800.0% | >999% | +990.0% | +8.0% | +11.1% | +149.2% | +176.1% |